

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,800

Open access books available

122,000

International authors and editors

135M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Introductory Chapter: Depigmentation

Tae-Heung Kim

1. Introduction

Depigmentation, lightening of the skin and mucosa, can be caused by local or systemic conditions, and there may be partial or complete loss of pigment [1]. Although depigmented patches may not matter in Caucasians, it is very serious for pigmented skin [2]. Depigmentation can also be a therapeutic goal for cosmetic treatment. Many vitiligo patients, who received depigmentation treatment, experience paradoxical jealousy because of their clean white skin. To improve facial blemishes, many people spend their money for laser, chemical peel, and cosmeceutical [3, 4].

Depigmentation can occur hereditarily or acquiredly. Hereditary diseases of depigmentation includes following diseases (**Figure 1**) [3]. Oculocutaneous albinism consists of a group of genetic disorders characterized by diffuse pigmentary dilution due to a partial or total absence of melanin pigment within melanocytes of the skin and eyes. Piebaldism is an genetic disorder characterized by poliosis and congenital, stable, circumscribed areas of leukoderma due to an absence of melanocytes within involved sites. Waardenburg syndrome is a rare genetic disease characterized by various combinations of depigmentation of skin and irides, and congenital deafness. Hermansky–Pudlak syndrome is a rare genetic disease of depigmentation showing pigmentary dilution of the skin, hair, and eyes, and serious systemic manifestations including hematopoietic, immune, pulmonary, renal, and cardiac symptoms. Chédiak–Higashi syndrome is a rare genetic disorder showing features of oculocutaneous albinism, ocular symptoms, hematologic and neurologic manifestations. Tuberous sclerosis complex is an autosomal dominant disorder characterized by neurologic disorders and skin findings including depigmented macules. Depigmentation along the lines of Blaschko reflects mosaicism characterized by a clone of skin cells with a decreased ability to make pigment. Hypomelanosis of Ito, linear nevoid hypopigmentation and nevus depigmentosus are considered to represent manifestations of cutaneous mosaicism.

Acquired diseases of depigmentation includes vitiligo, hypomelanosis secondary to cutaneous inflammation (postinflammatory hypopigmentation, pityriasis alba, sarcoidosis, hypopigmented mycosis fungoides, lupus erythematosus and lichen sclerosus et atrophicus), infectious hypomelanosis (tinea versicolor, leprosy, kala azar...), chemical or pharmacologic hypomelanosis (chemical leukoderma, hypomelanosis by strong steroid), hypomelanosis from physical agents (burn, laser, abrasion...), and miscellaneous (idiopathic guttate hypomelanosis, persistent macular hypomelanosis...) (**Figure 2**) [3].

Diseases of depigmentation can occur hereditarily or acquiredly. Hereditary diseases of depigmentation were reviewed excellently by Prof. Carrasquillo and colleagues. Albinism, piebaldism, white patches of tuberous sclerosis, Hermansky–Pudlak syndrome, Chédiak–Higashi syndrome, Waardenburg syndrome, and




Figure 1. Hereditary diseases of depigmentation. a. White forelock of piebaldism. b. Piebaldism affecting legs. c. Linear nevoid hypopigmentation. d. Nevus depigmentosus.

pigmentary mosaicism including hypomelanosis of Ito and nevus depigmentosus would be examples of them (**Figure 1**) [3].

Acquired diseases of depigmentation includes vitiligo, hypomelanosis secondary to cutaneous inflammation (postinflammatory hypopigmentation, pityriasis alba, sarcoidosis, hypopigmented mycosis fungoides, lupus erythematosus and lichen sclerosus et atrophicus), infectious hypomelanosis (tinea versicolor, leprosy, kala azar...), chemical or pharmacologic hypomelanosis (chemical leukoderma, hypomelanosis by strong steroid), hypomelanosis from physical agents (burn, laser, abrasion...), and miscellaneous (idiopathic guttate hypomelanosis, persistent macular hypomelanosis...) (**Figure 2**) [3].

Vitiligo is a common acquired disease of depigmentation, and afflicts and frightens so many patients. In vitiligo, melanocytes that produces melanin pigment of the skin are destroyed, and it can occur systemically to affect whole body or locally/segmentally affecting part of the body (**Figure 2a** and **b**) [3].

For the treatment of vitiligo, various lasers including 308 nm excimer laser are used successfully which has been used additionally with phototherapy and topical or systemic medications [5].

In patients with extensive vitiligo, depigmentation can be an easier and cosmetically more acceptable option. It includes various chemical and physical modalities.



Figure 2.
Acquired diseases of depigmentation. a. Systemic vitiligo affecting the whole body. b. Segmental vitiligo affecting one side of the body with white hairs (poliosis). c. Pityriasis alba, hypomelanosis secondary to cutaneous inflammation of atopic dermatitis. d. Hypomelanosis by tinea versicolor. e. Hypomelanosis by strong steroid (injection of triamcinolone acetonide). f. Hypomelanosis from physical injury induced by burn. g. Hypomelanosis from physical injury induced by abrasion wound. h. Idiopathic guttate hypomelanosis in older patients which belong to miscellaneous hypopigmentation.




Figure 3. Depigmentation therapies for vitiligo. *a.* Systemic vitiligo patient before depigmentation therapy by 20% mono-benzyl-ether of hydroquinone (MBEH). *b.* Systemic vitiligo patient after 6 months of depigmentation therapy by 20% MBEH. *c.* Systemic vitiligo patient before 308 nm excimer laser therapy. *d.* Systemic vitiligo patient after 6 months of 308 nm excimer laser therapy.

As in **Figure 3a** and **b**, depigmentation therapy can be an ideal treatment for advanced vitiligo patients. But cases presented in **Figure 3c** and **d** suggests restoring normal pigmentation is also an excellent option, and it would be better to be decided by patient's choice.

Cosmeceutical for depigmentation is a big market field for investigators and cosmetic companies. We have tragic experiences of chemical leukoderma and vitiligo induced by depigmentation cosmetics manufactured by Kanebo containing rhododendrol [6, 7]. Researchers put tremendous efforts to overcome it and there are a lot of active researches to find out newer materials for depigmentation [4, 7].

IntechOpen

IntechOpen

Author details

Tae-Heung Kim
White-Line Skin Clinic and Research Center, Changwon, Kyungnam, Korea

*Address all correspondence to: derkim@paran.com

IntechOpen

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

References

- [1] Wikipedia. Depigmentation. 2019. Available from: <https://en.wikipedia.org/wiki/Depigmentation>
- [2] Choi S, Kim DY, Whang SH, Lee JH, Hann SK, Shin YJ. Quality of life and psychological adaptation of Korean adolescents with vitiligo. *Journal of the European Academy of Dermatology and Venereology*. 2010;24(5):524-529
- [3] Passeron T, Ortonne J-P. Vitiligo and other disorders of hypopigmentation. In: Bologna JL, Schaffer JV, Cerroni L, editors. *Dermatology*. 4th ed. Amsterdam, Netherlands: Elsevier Co; 2018. pp. 1087-1114
- [4] Couteau C, Coiffard L. Overview of skin whitening agents: Drugs and cosmetic products. *Cosmetics*. 2016;3(3):27. <https://doi.org/10.3390/cosmetics3030027>
- [5] Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Vitiligo Working Group. Current and emerging treatments for vitiligo. *Journal of the American Academy of Dermatology*. 2017 Jul;77(1):17-29
- [6] Harris JE. Chemical-induced vitiligo. *Dermatologic Clinics*. 2017;35(2):151-161
- [7] Tokura Y, Fujiyama T, Ikeya S, Tatsuno K, Aoshima M, Kasuya A, et al. Biochemical, cytological, and immunological mechanisms of rhododendrol-induced leukoderma. *Journal of Dermatological Science*. 2015 Mar;77(3):146-149